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summARy – ovarian hyperstimulation syndrome (ohss) is a rare and potentially life-thre-
atening complication of infertility treatment occurring during either the luteal phase or early pre-
gnancy. An increasing number of thromboembolic complications associated with the increased use 
of assisted reproductive techniques have been reported in the literature. identification of the risk 
factors is crucial for prevention of thromboembolic events in ohss patients. Alterations in the 
hemostatic system cause hypercoagulability in women affected by severe ohss. Coexistence of 
inherited hypercoagulable conditions increases the risk of thromboembolism. The role of clinical pa-
rameters that can help predict development of thrombosis is controversial. patients with a personal 
or family history of thrombosis undergoing infertility treatment should be considered for thrombop-
hilia screening, while routine examination of inherited thrombophilic mutations is not indicated in 
infertile patients. Antithrombotic primary prevention is not indicated in healthy women undergoing 
assisted reproductive procedures or in women with thrombophilia. Anticoagulant therapy is indic-
ted if there is clinical evidence of thrombosis or laboratory evidence of hypercoagulability. in this 
review, the risks of hypercoagulability in the ohss are discussed.
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Introduction
ovarian hyperstimulation syndrome (ohss) is 
one of the most frequently reported complications of 
infertility treatment occurring during either the luteal 
phase or early pregnancy. it is usually associated with 
the use of exogenous gonadotropins for ovarian stim-
ulation, or occasionally with the use of clomiphene 
citrate. some forms of ohss are rarely associated 
with a spontaneous ovulatory cycle. The incidence of 
ohss varies according to different studies. The over-
all incidence of ohss is estimated at 0.6%-14% of 
all ovarian stimulation cycles1. severe ohss accounts 
for 0.5% to 5% of all cases of ohss1. The risk factors 
for developing severe form of ohss include high or 
rapidly rising estradiol levels (with serum concentra-
tion >2500-3500 pg/ml), great numbers of large and 
medium-sized follicles and the number of oocytes re-
trieved during in vitro fertilization (ivf; >14), pre-
vious episodes of ohss, age under 30 years, use of 
gonadotropin releasing agonist protocol, higher or re-
peated dose of human chorionic gonadotropin (hCg), 
and polycystic ovarian syndrome (pCos)2,3.
Thromboembolic phenomena are an uncommon 
complication of ohss and sometimes fatal despite 
appropriate treatment4. it is estimated that one of 128 
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women with severe ohss develops thromboembolic 
disease5.
Pathophysiology of Thrombosis
The etiology of ohss is complex, but hCg, ei-
ther exogenous (to induce ovulation or as a luteal 
phase support) or endogenous (pregnancy derived), is 
believed to be a main promoter of ohss. first step 
in the pathophysiology of ohss is hCg stimula-
tion of granulosa-lutein cells, leading to the increased 
production of vascular endothelial growth factor 
(vegf)6,7. A number of other molecules, includ-
ing angiogenin, interleukin(il)-1, il-2, il-6, il-
10, il-18, tumor necrosis factor-alpha, insulin-like 
growth factor 1, epidermal growth factor, transform-
ing growth factors, von Willebrand’s factor (vWf), 
endothelial adhesion molecules, endothelin-1, hista-
mines and ovarian kinin-kallikrein and ovarian-renin 
angiotensin system, take part in the increased capil-
lary permeability, ovarian neovascularization, inflam-
matory response and inhibition of hepatic albumin 
production, which explains most of the symptoms 
and signs of ohss8,9. vegf is the pivotal cytokine 
involved in the pathophysiology of ohss. it acts 
dominantly through the vegf receptor-2 increas-
ing vascular permeability with loss of fluid, proteins 
and electrolytes into the extravascular compartment. 
severe ohss is a potentially life-threatening iatro-
genic complication accompanied by massive ovarian 
enlargement, intravascular volume depletion with ac-
companying development of edema, ascites, hydrotho-
rax, abdominal distension, electrolyte disturbance, 
hypoalbuminemia, hemoconcentration and ultimately 
thromboembolism, liver and renal insufficiency and 
multiple organ failure with adult respiratory distress 
syndrome2. The exact pathogenesis of thrombosis in 
ohss has not yet been elucidated entirely. it has 
been surmised that the hypercoagulable state is cre-
ated due to hemoconcentration, as a result of the in-
creased capillary permeability, which leads to the loss 
of protein-rich fluid from the intravascular compart-
ment into the third space, and blood viscosity together 
with changes in coagulation parameters. both arterial 
and venous thrombosis in ohss demonstrate predi-
lection for head and neck manifestation. bauersachs 
et al.10 offer a pathophysiological explanation for this 
phenomenon. estrogen-rich lymph collected from as-
cites into the lymphatic system, which further drains 
into the junction of the subclavian vein and jugular 
veins, can cause local high estrogen content, trigger-
ing thrombosis in these neck veins10. The concentra-
tion of estradiol in the ascites fluid is 27 times higher 
than the serum concentration10. other substances 
drained from the lymphatic system into the veins may 
cause additional prothrombotic output. salomon et al. 
hypothesize that the development of thrombosis early 
in pregnancy is the result of mechanical compression 
mediated by rudimentary brachial cysts filled with 
fluid during ohss11. further studies are required to 
fully understand this phenomenon. 
Thrombotic Risk Factors
in a cross sectional study, henriksson et al.12 ana-
lyzed 23,498 women who gave birth after ivf and 
116,960 individually matched women with natural 
pregnancies and showed an increased risk of throm-
boembolism and pulmonary embolism in pregnant 
women after ivf, especially during the first trimester. 
in their study, venous thromboembolism (vTe) oc-
curred in 4.2/1000 women after ivf versus 2.5/1000 
in women with natural pregnancies. The risk of vTe 
after ivf was significantly increased throughout 
pregnancy, especially during the first trimester. pul-
monary embolism occurred in 3.0/10 000 women after 
ivf during the first trimester, compared with 0.4/10 
000 in women with natural pregnancies. The absolute 
risk of pulmonary embolism was low12. Their results 
are in accordance with the findings reported by Rova 
et al.13, on the risk of first-trimester vTe in women 
after ivf being tenfold that recorded in women with-
out ivf. pregnant women after ivf in the absence of 
ohss had a fivefold risk of vTe, while pregnancies 
after ivf that were complicated by ohss had a 100-
fold risk of vTe. There was no increased risk of vTe 
after the first trimester13. 
several studies investigated the alterations of the 
hemostatic system in women affected by severe ohss. 
Considering laboratory findings, increased levels of 
factors i and v, platelets and fibrinolytic inhibitors 
have been reported in patients with ohss14. Aune 
et al.15 analyzed the effects on blood coagulation and 
fibrinolytic activity during ovarian stimulation. They 
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found a marked increase in the clot lysis time, a rise 
in plasma fibrinogen concentration and reduction in 
antithrombin iii concentration. The blood fibrinolyt-
ic activity was significantly reduced. Rogolino et al.16 
report that d-dimer, tissue factor (Tf), thrombin-
antithrombin complexes, prothrombin fragment 1 + 
2 (f1+2), plasmin-antiplasmin complexes (pAp), and 
vWf antigen plasma levels were significantly higher 
in patients with severe ohss as compared with those 
observed in both case-control group and healthy con-
trols. plasma levels of the tissue factor pathway inhib-
itor (Tfpi) were significantly lower. They also found 
that d-dimer levels were related to serum estradiol 
levels and number of recovered oocytes. The authors 
concluded that marked hypercoagulability with alter-
ations in Tf and Tfpi levels determined the clinical 
outcome of severe ohss. in addition to these chang-
es, there is a reduced protein C and protein s activity 
and decreased levels of tissue plasminogen activator 
and plasminogen activator inhibitor type i (pAi-1) 
as well17. These results indicate an increased risk of 
hypercoagulability following ovarian stimulation for 
ivf. in the analysis of longitudinal studies, Chan17 
concludes that activation in both the coagulation and 
fibrinolysis systems occurs in patients undergoing 
ovarian stimulation, and that this activation is greatly 
exaggerated with the development of ohss. besides 
the laboratory findings mentioned, the possible risk 
factors for thromboembolism in severe ohss are el-
evated serum estradiol levels at the end of ovulation 
induction, presence of antiphospholipid antibody syn-
drome, factor ii (fii) g20210A mutation and factor 
v leiden (fvl) g16191A mutation17. some authors 
recommend screening for genetically determined 
risk factors before ovulation induction, especially in 
patients with personal and family history of throm-
bosis2. febregues et al.18 report that screening for fii 
and fvl mutation in an ivf general population is 
not cost-effective and that the prevalence of thrombo-
philia is not increased in patients with severe ohss, 
which is in contrast to the results of a previous study by 
dulitzky et al.19, who found an increased prevalence of 
thrombophilia in women with severe ohss. machac 
et al.20 found an increased heterozygous form of fvl 
mutation in infertile patients. however, carriers of 
this mutation did not have an increased risk of devel-
oping severe form of ohss during stimulation. Ricci 
et al.21 compared the prevalence of fii and fvl mu-
tation between women undergoing ivf and women 
with spontaneous pregnancy; and the ivf outcomes 
and the risk of complications in fvl and fii carrier 
versus non-carrier women. no thrombotic complica-
tions occurred in either group. They conclude that the 
presence of fvl and fii mutations in asymptomatic 
women and in the absence of other risk factors does 
not influence ivf outcome, does not represent a risk 
factor for ohss, and does not favor thrombosis after 
ivf. Although the coexistence of thrombophilia and 
ohss can have fatal consequences, routine exami-
nation for inherited thrombophilic mutations is not 
indicated in infertile patients20,21. only patients with 
a personal or family history of thrombosis undergoing 
ivf should be considered for thrombophilia screen-
ing22. identification of the risk factors is crucial for 
prevention of ohss.
Thromboembolic Complications 
The incidence of thromboembolic events in as-
sisted reproductive techniques (ART) has been es-
timated to 0.08%-0.11%23. Rao et al.24 performed a 
review of thromboembolic cases associated with ovar-
ian stimulation, including 54 cases between 1964 and 
1997, previously reported by stewart et al. sixty-seven 
percent of the 97 cases with thrombotic events after 
ovulation induction were of venous origin, while 33% 
were arterial thromboses. seventy-four percent of 
these cases were associated with ohss and 77% were 
associated with pregnancy22. in pregnancy, venous 
thrombosis is often located in lower extremities, most 
commonly in the ileofemoral region24, while venous 
thrombosis in ohss usually involves veins in the 
neck and upper extremities (71%-80%)17,24. pulmo-
nary thromboembolism occurs in 4%-12% of ohss 
patients, complicated with deep vein thrombosis25,26. 
venous thrombosis often presents several weeks af-
ter resolution of ohss, while arterial event usually 
occurs concurrently with ohss development14,24. 
of the arterial thromboembolic events, most com-
mon are cerebrovascular accidents (60%), followed by 
extremities (17%) and myocardial infarction (11%)17. 
Chan17 has presented a review of 96 english-language 
articles on thromboembolism associated with ohss 
reported until december 2008. in Chan’s review, 
Acta Clin Croat,  Vol. 54,   No. 2,  2015 18�
d. danolić et al. ovarian hyperstimulation syndrome
mortality among reported arterial thrombosis cases 
was 9%. There was no mortality reported among ve-
nous thrombosis cases17. our literature review using 
the medline database identified additional 14 well 
documented cases of venous and arterial thrombosis 
associated with ART (January 2009-August 2014). 
We found additional 12 articles reporting on venous 
thrombosis27-38, and two articles reporting on arterial 
thrombosis after ovarian stimulation39,40.
of the arterial thromboembolic reports, one pa-
tient had cerebrovascular accident and another one 
right femoral artery thrombosis39,40. The predominant 
sites of venous thrombosis involvement were the in-
ternal and external jugular veins27-29,31,36,38, sporadi-
cally combined with subclavian vein thrombosis27,36. 
one patient had combined jugular vein thrombosis, 
subclavian vein thrombosis and right brachiocepha-
lic vein thrombosis after ivf and embryo transfer30. 
Three patients had cerebral venous thrombosis32,34,37, 
while one of them had dual cerebral vein thrombosis 
affecting rectal sinus and left transverse sinus37. in pa-
tients that develop progressive abdominal pain during 
and after ART, mesenteric vein thrombosis and portal 
vein thrombosis should be considered on differential 
diagnosis33,35, even in the absence of ohss33.
Thrombosis Prevention and Treatment 
based on the existing literature, antithrombotic 
primary prevention is not indicated in healthy women 
undergoing assisted reproductive procedures, or in 
women with thrombophilia41. Women with severe 
ohss require hospitalization for careful monitoring 
and appropriate treatment. The main interventions are 
fluid management and correction of hypovolemia and 
hemoconcentration. intravenous hydration should be 
started with a crystalloid solution to alleviate hemo-
concentration and provide adequate end-organ per-
fusion. if end-organ perfusion is not maintained, an 
alternate colloid solution should be administered42. 
Transvaginal ascitic fluid aspiration should be per-
formed in patients with tense ascites to alleviate their 
discomfort, and according to Qublan et al.43, if re-
peated (>3) it significantly increases pregnancy rate 
along with a significant decrease in the abortion rate. 
Anticoagulant therapy is indicated if there is clini-
cal evidence of thrombosis or laboratory evidence of 
hypercoagulability2. Thromboprophylaxis should not 
be prescribed for women with a family history of 
thrombosis and early start of ohss after eT with 
no other risk factors (previous vTe, thrombophilia, 
age over 35, obesity, parity >4, gross varicose veins, 
paraplegia, inflammatory disorders, e.g., inflamma-
tory bowel disease, nephrotic syndrome, certain car-
diac diseases, myeloproliferative disorders, hyperem-
esis and dehydration). To prevent thrombosis in severe 
ohss, subcutaneous heparin 5000-7500 iu/day and 
use of thromboembolic deterrent stockings should be 
instituted and continued until discharge25,42.  Throm-
boprophylaxis in severe form of ohss does not al-
ways prevent thrombosis44-46. Acute management of 
patients that develop venous thrombosis involves the 
use of adjusted-dose low molecular weight heparin 
(lmWh) or intravenous unfractionated heparin (iv 
ufh) for at least 5 days, followed by adjusted-dose 
ufh or lmWh for the remainder of pregnancy and 
at least 6 weeks postpartum47. The preferred option 
for most patients is lmWh due to better bioavail-
ability, longer plasma half-life, and better safety pro-
file with regard to osteoporosis and thrombocytopenia 
compared to ufh48,49. lmWh and ufh are safe for 
the fetus, due to the inability to pass placental barrier. 
bleeding at the uteroplacental junction is possible49. 
for cerebrovascular accidents and myocardial infarc-
tion, specific treatment with lmWh and ufh is 
the same as in the general population17,47,50. Acute 
reperfusion in selected patients with myocardial in-
farction may be achieved with percutaneous coronary 
intervention and/or fibrinolytic agents under strict 
protocols17,47. The rate of thrombosis progression in 
ohss despite administration of anticoagulant ther-
apy is 7.5%17. multidisciplinary approach in the treat-
ment of critical ohss is required for its appropriate 
management.
Conclusion
ovarian hyperstimulation syndrome is the main 
risk factor for thrombosis complicating controlled 
ovarian hyperstimulation and ovulation induction. 
prevention of the syndrome is the most important 
aspect of its management. Apart from cycle cancel-
ling, all other preventive methods may reduce but not 
eliminate ohss. Antithrombotic treatment is crucial 
1�0 Acta Clin Croat,  Vol. 54,   No. 2,  2015
d. danolić et al. ovarian hyperstimulation syndrome
if there is clinical evidence of thrombosis or laboratory 
evidence of hypercoagulability. 
further studies will complement our knowledge 
of thromboembolic phenomena in ohss, which may 
advance our ability to predict, prevent and treat this 
rare, but life-threatening complication of ART.
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sažetak 
RiZik hipeRkoAgulAbilnosTi kod sindRomA hipeRsTimulACiJe JAJnikA
D. Danolić, M. Kasum, M. Puljiz, I. Alvir, D. Tomica, I. Mamić, E. Čehić i I. Bolanča
sindrom hiperstimulacije jajnika je rijetka i za život opasna komplikacija liječenja neplodnosti koja se javlja u luteal-
noj fazi menstruacijskog ciklusa ili tijekom rane trudnoće. povećanjem zastupljenosti tehnika potpomognute oplodnje 
povećava se broj prijavljenih slučajeva tromboembolijskih komplikacija. u prevenciji tromboembolijskih događaja kod 
bolesnica sa sindromom hiperstimulacije jajnika ključno je određivanje rizičnih čimbenika. promjene u sustavu hemostaze 
uzrokuju hipekoagulabilnost, a nasljedne trombofilije dodatno povećavaju rizik tromboembolije. sporna je uloga kliničkih 
parametara koji mogu pomoći u predviđanju razvoja tromboze. Žene podvrgnute liječenju neplodnosti koje su preboljele 
tromboembolijsku bolest ili u obitelji imaju slučajeve tromboembolijske bolesti treba testirati na nasljedne trombofilije, dok 
se rutinsko testiranje kod neplodnih žena ne provodi. Antitrombotska terapija je indicirana samo ako su prisutni klinički 
znakovi tromboze ili laboratorijski dokazana hiperkoagulabilnost, a nije indicirana kod žena s nasljednom trombofilijom 
u postupku medicinski potpomognute oplodnje bez kliničkih i/ili laboratorijskih znakova tromboze. u ovom preglednom 
članku opisani su rizici hiperkoagulabilnosti u sindromu hiperstimulacije jajnika.
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